Navigation Links
Patients, Physicians Rely on ChemoFx(R) to Support Their Cancer Treatment Decisions
Date:2/3/2010

PITTSBURGH, Feb. 3 /PRNewswire/ -- An era of personalized medicine is redefining how patients and doctors work together to fight cancer.  Now, drug response markers such as the ChemoFx® diagnostic test show promising results which can help to determine individual cancer treatment plans when using various chemotherapeutic agents.

ChemoFx® is a test produced by Precision Therapeutics, Inc., a life sciences company in Pittsburgh, Pennsylvania. With the introduction of this innovative drug response marker, the company has pioneered a method of identifying cancer cell response and sensitivity to various chemotherapeutic and biologic agents at the biopsy stage -- long before a patient actually begins chemotherapy -- providing a custom blueprint of a patient's probable tumor response.

The result is valuable insight into which chemotherapy drugs are most likely to work in an individual cancer patient's own body -- along with those that are unlikely to be effective in shrinking and killing the cancerous tumor.  This information can then be used to help guide chemotherapy treatment decisions, according to company officials.

"Patients and their physicians will have an understanding of how chemo will impact the cancer cells themselves long before it impacts the patient," says Sean McDonald, CEO of Precision Therapeutics.  "By testing multiple agents on a patient's cancer cells in the lab, ChemoFx® determines the chemotherapies that are more likely to be effective and avoid those that are likely to be ineffective, giving patients a powerful advantage in their fight against cancer."

The diagnostic test works by taking a sample of a patient's tumor, which is removed during biopsy or surgery, and sending that sample to the Precision Therapeutics laboratory for sensitivity and resistance testing. In a controlled environment that closely parallels what happens within the human body itself, those cells are incubated and treated by a fully automated system with a number of chemotherapy and biologic agents selected by that patient's physician.  Precision Therapeutics then sends the physician a report that details how the cancerous cells responded to each drug or chemotherapy combination. Integrating the results with clinical judgment, the physician can then use the report to support his decision on a treatment regimen for the patient, with the tandem objective of eradicating the disease and optimizing quality of life during chemotherapy treatment.

With the national movement toward cancer patient advocacy gaining momentum, those newly diagnosed are now engaging with their treating physician as both patient -- and partner -- in making cancer treatment decisions.  

"Today's cancer patients are informed, empowered self advocates," according to McDonald.  "They want a voice in their own treatment options.  A key discussion points is the topic of personalizing medicine through testing services such as ChemoFx.  Each and every patient's cancer is unique, making the need for individual, custom drug response markers all the more critical to support a patient's treatment plan. They want their first step to be the right step."

"When you're diagnosed with cancer, your strongest ally is information," says McDonald.  "That means talking with your doctor to plan your best course of action together.  We encourage you to test the tumor first, find out how it responds, and based on those findings and your physicians clinical judgment, determine the optimal treatment plan for your individual cancer."

About Precision Therapeutics

Precision Therapeutics, a life science company and leader in the development of innovative technology, delivers personalized diagnostics to physicians with the goal of supporting and optimizing difficult treatment decisions.

For more information, please visit www.precisiontherapeutics.com or www.ChemoFX.com

SOURCE Precision Therapeutics, Inc.

RELATED LINKS
http://www.precisiontherapeutics.com

'/>"/>

SOURCE Precision Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medicare Announces Expanded Coverage for Anticoagulation Patients, Opening the Door for More Patients to Test PT/INR at Home
4. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
5. Knowledge Based Reconstruction Demonstrates Accuracy in Obtaining Ventricular Volume and Function in Tetralogy of Fallot Patients, According to VentriPoint Diagnostics
6. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
7. Avastin(R) Shows Unprecedented Benefits in Colorectal Cancer Patients, Irrespective of K-Ras Gene Mutation
8. Bioimpedance Spectroscopy is More Accurate and Reliable Than Other Methods of Subclinical Assessment of Lymphedema in Breast Cancer Patients, According to Paper Published in Journal of Clinical Oncology
9. RAD001 Shows Potential to Reverse Resistance to Herceptin(R)* in Metastatic Breast Cancer Patients, Leading to Phase III Trial
10. For Old or Young Dialysis Patients, AV Fistulas Remain Pure Gold
11. Virtual Colonoscopies Show Value for Some Patients, But Polyps Will Be Missed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/28/2017)... 28, 2017 Hill-Rom Holdings, Inc. (NYSE: HRC), ... call and webcast on Friday, November 3, 2017, beginning ... ending at approximately 8:30 a.m. (CDT) / 9:30 a.m. ... 2017 financial performance and guidance for 2018, Hill-Rom executives ... enhance operational performance, and long-range financial outlook through 2020. ...
(Date:9/25/2017)... PROVIDENCE, R.I. , Sept. 25, 2017 /PRNewswire/ ... immunogenicity assessment, vaccine design, and immune-engineering today announced ... focused on the development of personalized therapeutic cancer ... and has provided exclusive access to enabling technologies ... MSc Eng., MBA will lead EpiVax Oncology as ...
(Date:9/19/2017)...   ZirMed Inc ., a recognized leader in cloud-based ... has been ranked #1 by its users for the seventh ... User Survey. ZirMed was recognized as the top-ranked end-to-end revenue ... centers over 200 beds and holds one of the longest ... history. ...
Breaking Medicine Technology:
(Date:10/13/2017)... Ky. (PRWEB) , ... October 13, 2017 , ... The ... MPH to become its next President and Chief Executive Officer, succeeding Dr. James C. ... CEO Elect beginning July 1, 2018 until Dr. Puffer’s retirement at the end of ...
(Date:10/13/2017)... ... ... PurhealthRX , a leading Health and Nutrition Company, is announcing the ... spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the amount ... into liquid products, while reducing costs to end users. , The team of researchers ...
(Date:10/13/2017)... ... 2017 , ... Lori R. Somekh, founder of the Law Office of ... elder law and special needs planning attorneys. “Membership in ElderCounsel helps our office remain ... to network with elder law attorneys nationwide,” said Somekh. , ElderCounsel ...
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
Breaking Medicine News(10 mins):